RBC Life Sciences net sales increase 18% to $7.9 million in second quarter 2014

Aug 14 2014

RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $7.9 million for the quarter ended June 30, 2014, an 18% increase over net sales of $6.7 million in the second quarter of 2013. The Company reported a second quarter net loss of $7,000, or $0.00 per share, compared to a net loss of $147,000, or $0.07 per share, for the same quarter last year. Net sales were $13.6 million for the six months ended June 30, 201, a 10% increase over net sales of $12.4 million in the same period last year. For the six months ended June 30, 2014 the Company reported a net loss of $385,000, or $0.17 per share, compared to a net loss of $155,000, or $0.07 per share, in the comparable period in 2013. All per share amounts have been restated to reflect the 1-for-500 reverse stock split and 50-for-1 forward stock split affected on August 9, 2013.

"The Company has focused in the last few years on expansion in Southeast Asia and promoting our lead product Stem-Kine™, a nutritional supplement that has been shown in human clinical studies to enable the body to produce more stem cells. We are pleased with the increasing sales of Stem-Kine as more and more people become aware of the benefits of autologous stem cells through reports on hundreds of clinical trials being conducted throughout the world," said RBC Life Sciences CEO, Clinton H. Howard.

Mr. Howard continued, "Sales of Nutritional Products through our network of independent Associates increased 64% during the second quarter of 2014 compared with Associate network sales in the same quarter last year. Sales of Nutritional Products to our foreign licensees increased 3% in the second quarter of this year compared to the same period in 2013. During the second quarter, we opened our fourth training and distribution center in Southeast Asia located in Jakarta, Indonesia."

SOURCE RBC Life Sciences, Inc.